Alterity Therapeutics Ltd has released a press release.
ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Appendix 4C and Quarterly Cash Flow Report
- US patent grant and license agreement
- First Patient Enrolled in Europe in Phase II Clinical trial
- Regulatory approval for Phase II trial in France and Austria
- ATH434 Clinical Trial Launched in Italy
Later from Alterity Therapeutics
- Investor Presentation
- Ph 2 Data Monitoring Committee Recommends Continuing Trial
- Alterity receives a $4.74 million R&D Tax Refund
- Alterity Granted New Composition of Matter Patent in Europe
- Alterity Presents New Data on Multiple System Atrophy
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics